Literature DB >> 10199802

Comment--Is there a role for low doses of mitotane (o,p'-DDD) as adjuvant therapy in adrenocortical carcinoma?

L Barzon, F Fallo, N Sonino, O Daniele, M Boscaro.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10199802     DOI： 10.1210/jcem.84.4.5625-3

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN： 0021-972X            Impact factor:   5.958


× No keyword cloud information.
  4 in total

Review 1.  Current perspective in the diagnosis and treatment of adrenocortical carcinoma.

Authors:  D E Schteingart
Journal:  Rev Endocr Metab Disord       Date:  2001-08       Impact factor: 6.514

Review 2.  Adrenocortical carcinoma: the management of metastatic disease.

Authors:  André P Fay; Aymen Elfiky; Gabriela H Teló; Rana R McKay; Marina Kaymakcalan; Paul L Nguyen; Anand Vaidya; Daniel T Ruan; Joaquim Bellmunt; Toni K Choueiri
Journal:  Crit Rev Oncol Hematol       Date:  2014-06-04       Impact factor: 6.312

Review 3.  Cytotoxic treatment of adrenocortical carcinoma.

Authors:  H Ahlman; A Khorram-Manesh; S Jansson; B Wängberg; O Nilsson; C E Jacobsson; S Lindstedt
Journal:  World J Surg       Date:  2001-07       Impact factor: 3.352

4.  Sustained remission of metastatic adrenal carcinoma during long-term administration of low-dose mitotane.

Authors:  I Ilias; M Alevizaki; G Philippou; E Anastasiou; A Souvatzoglou
Journal:  J Endocrinol Invest       Date:  2001 Jul-Aug       Impact factor: 4.256
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.